Pharvaris N.V 6-K, filed Aug 12, 2026
Pharvaris N.V. (PHVS)
About this 6-K
Pharvaris N.V filed this 6-K on August 12, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August
Commission File Number: 001-40010
(Translation of registrant’s name into English)
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
PHARVARIS N.V.
On August 12, 2026, Pharvaris N.V. issued a press release reporting financial results and other business updates for the three and six months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act. Exhibits 99.2 and 99.3 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-273757, 333-277705 and 333-278650) and Form S-8 (Registration Number 333-252897) of Pharvaris N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
Exhibit No. |
|
Description |
|
||
|
||
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PHARVARIS N.V. |
|
|
|
|
Date: August 12, 2026 |
By: |
/s/ Berndt Modig |
|
Name: |
Berndt Modig |
|
Title: |
Chief Executive Officer |
Exhibit 99.1
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
ZUG, Switzerland, August 12, 2026 – Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the second quarter ending on June 30, 2026, and provided a business update.
“Pharvaris continues to make strong progress advancing deucrictibant IR toward potential regulatory approval, moving closer to our goal of helping address unmet needs of people living with HAE by providing a therapy that can offer rapid and sustained attack relief and resolution with a single oral capsule. In parallel to our recent regulatory successes, our ongoing pre-commercial activities are designed to support a timely, successful U.S. launch,” said Berndt Modig, Chief Executive Officer of Pharvaris. “Announcing pivotal data from CHAPTER-3, expected this quarter, will mark another key milestone for Pharvaris as we develop deucrictibant for both the prevention and on-demand treatment of bradykinin-mediated angioedema attacks. The financing we completed in May extends our cash runway into 2028, enabling us to properly prepare for deucrictibant’s launch and consider lifecycle management opportunities while maintaining capital discipline.”
Recent Business Updates
Development Pipeline
Corporate
Upcoming Investor Events
Date, time: Wednesday, Sept. 9, 4:30 p.m. EDT
Date, time: Thursday, Sept. 10, 1:00 p.m. EDT
Date, time: Tuesday, Sept. 15, 7:45 a.m. EDT
Date, time: Wednesday, Sept. 16, 8:00 a.m. EDT
Live audio webcasts of the presentations will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. The audio replays will be available on Pharvaris’ website for 30 days following the presentation.
Upcoming Medical Congress Presentations
Presenter: Niklas Piet Doering, Ph.D.
Format: Oral Presentation
Abstract ID: 158012
Date, time: Thursday, September 3, 14:55-15:05 CEST (8:55-9:05 a.m. EDT)
Presenter: Marc A. Riedl, M.D., M.S.
Format: Oral Presentation
Abstract ID: 158394
Date, time: Friday, September 4, 9:20-9:30 CEST (3:20-3:30 a.m. EDT)
Presenter: Brigitte Loenders, Ph.D.
Format: Poster Presentation
Abstract ID: 157799
Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT)
Presenter: Juan Bravo, Ph.D.
Format: Poster Presentation
Abstract ID: 157800
Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT)
Presenter: Emel Aygören-Pürsün, M.D.
Format: Poster Presentation
Abstract ID: 157804
Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT)
Presenter: Marcin Stobiecki, M.D., Ph.D.
Format: Poster Presentation
Abstract ID: 157807
Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT)
Presenter: Henriette Farkas, M.D., Ph.D., D.Sc.
Format: Poster Presentation
Abstract ID: 158385
Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT)
Presenter: Danny M. Cohn, M.D., Ph.D.
Format: Poster Presentation
Abstract ID: 158405
Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT)
Presenter: Jonathan DeGeer, Ph.D.
Format: Poster Presentation
Abstract ID: 158979
Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT)
Presenter: Juan Bravo, Ph.D.
Format: Poster Presentation
Abstract ID: 159172
Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT)
Financials
Second Quarter 2026 Financial Results
Note on International Financial Reporting Standards (IFRS)
Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. Pharvaris maintains its books and records in the Euro currency.
About Deucrictibant
Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By
delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.
Forward Looking Statements
This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “hope,” “estimate,” “may,” “could,” “should,” “would,” “will,” “intend” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; the outcome of regulatory approvals, including the outcome of our NDA for the on-demand treatment of acute attacks of HAE; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, and CHAPTER-1 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials, such as CHAPTER-3, and CREAATE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political
and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.
Contact
Maggie Beller
Vice President, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com
Exhibit 99.2
Management’s Discussion and Analysis of Financial Condition and Results of Operations
This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes thereto, for the three and six months ended June 30, 2026 and 2025 included as Exhibit 99.3 to the Report on Form 6-K to which this discussion is attached as Exhibit 99.2. We also recommend that you read “Item 4. Information on the Company”, “Item 5. Operating and Financial Review and Prospects” and our audited consolidated financial statements for fiscal year 2025, and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (the “SEC”). In addition, we recommend that you read any public announcements made from time to time by Pharvaris N.V.
The following discussion is based on our financial information prepared in accordance with the IFRS Accounting Standards (“IFRS”) as issued by the International Accounting Standards Board (the “IASB”), which may differ in material respects from generally accepted accounting principles in the United States and other jurisdictions. We maintain our books and records in euros. Unless otherwise indicated, all references to currency amounts in this discussion are in euros.
The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under “Item 3. Key Information—D Risk factors” in the Annual Report and under “Risk factors” in any other periodic filings with the Securities and Exchange Commission.
Unless otherwise indicated or the context otherwise requires, all references to “Pharvaris” or the “Company,” “we,” “our,” “ours,” “us”, or similar terms refer to Pharvaris N.V. and its subsidiaries.
Overview
We are a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Our first molecule, deucrictibant (previously referred to as PHA-022121 or PHA121), is a novel, oral, small-molecule bradykinin B2 receptor antagonist under development for the prevention or treatment of attacks due to bradykinin-mediated angioedema (AE-BK), including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). Deucrictibant has the potential to address unmet medical needs by bringing improvements beyond the therapeutic profile of existing medicines and providing patients with quality of life and convenience that is superior to current standard-of-care. We believe deucrictibant has the potential to provide injectable-like efficacy™ with a well-tolerated profile and the convenience of an oral therapy for both the prophylactic and on-demand treatment of HAE attacks.
Deucrictibant may address unmet medical needs of people living with AE-BK by both preventing attacks from occurring, using an extended-release (XR) tablet formulation of deucrictibant (previously referred to as PHVS719), and treating the manifestations of attacks, using an immediate-release (IR) capsule formulation of deucrictibant (previously referred to as PHVS416). The XR tablet formulation is designed to maintain therapeutic levels for over 24 hours and to achieve a steady-state plasma concentration within 72 hours, supporting a once-daily dosing regimen. The IR capsule formulation is designed to rapidly reach therapeutic exposure in order to mitigate HAE attacks symptoms rapidly and completely with a single oral dose.
In addition to the differentiation of our individual products, having on-demand and prophylactic products with the same active ingredient enables patients to maintain a trusted active medicine if they change their treatment approach by moving from on-demand to prophylactic treatment (or back). This may be particularly valued by children or adolescents who typically begin therapy with on-demand only and gradually move to prophylaxis as attack severity and/or frequency increase (commonly after puberty).
We reported topline data from RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in December 2025. Deucrictibant demonstrated a clinically differentiated profile by meeting the primary and all key secondary efficacy endpoints with statistical significance and was well tolerated. A New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks is currently under review with the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027. A Marketing Authorization Application (MAA) is currently under review with the European Medicines Agency (EMA).
In December 2024, we initiated CHAPTER-3, a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis of angioedema attacks in adults and adolescents (12 years and older) with HAE. We expect to report topline data from this study by September 30, 2026.
1
In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks.
A wide variety of events beyond our control, including natural or man-made disasters, power shortages, fires, extreme weather conditions, pandemics, epidemics or outbreaks of infectious diseases, political instability or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators or other third parties with whom we conduct business now or in the future. These events may cause businesses and government agencies to be shut down, supply chains to be interrupted, slowed, or rendered inoperable, and individuals to become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. Additionally, we are exposed to a variety of risks in the ordinary course of our business, including, but not limited to, foreign currency risk and interest rate risk. We regularly assess each of these risks to minimize any adverse effects on our business as a result of those factors. For a detailed discussion, see Note 17 to our consolidated financial statements included in the Annual Report.
In addition, the retaliatory measures that have been taken, or could be taken in the future, by the United States, NATO, and other countries with respect to the invasion of Ukraine and the conflict in the Middle East have created global security concerns that could result in regional conflicts and also adversely affect our ability to conduct ongoing and future clinical trials of our product candidates. For example, our RAPIDe-1 and CHAPTER-1 studies include a significant number of patients in Germany, Poland, and Bulgaria, and we have a patient in Israel. A further escalation of the conflicts in Ukraine or the Middle East may potentially impact our ability to complete our ongoing and planned clinical trials in these countries on a timely basis, or at all. Clinical trials in these countries could be suspended or terminated, and we may be prevented from obtaining data on patients already enrolled at affected sites. Any of the foregoing could impede the execution of our clinical development plans.
Financial Operations Overview
Revenues
We did not record any revenues during the period covered by the historical financial information included in this Report. We do not expect to recognize any product sales related revenues before we are able to commercialize our first product.
Research and development expenses
We are focused on the clinical development of deucrictibant. Since our inception, we have devoted substantially all of our resources to research and development efforts relating to the development of deucrictibant and our product candidates IR and XR. We expect that we will continue to incur significant research and development expenses as we seek to complete the clinical development of, and achieve regulatory approval for, our product candidates IR and XR, and in connection with discovery and development of any additional product candidates.
Research and development expenses consist of the following:
2
We expect our total research and development expenses to increase in 2026, driven by activities supporting the preparation and submission of the New Drug Application for IR to regulatory authorities, as well as the continued development of our XR product candidate and our clinical study in AAE.
There is a risk that any clinical development or product discovery program may not result in commercial approval. To the extent that we fail to obtain approval to commercialize our product candidate in a timely manner, we would need to continue to conduct nonclinical studies or clinical trials over a longer period of time, and we anticipate that our research and development expenses may further increase.
Clinical development timelines and associated costs may vary significantly and FDA approval of deucrictibant IR for the treatment of on-demand attacks in 2027 is highly uncertain. Moreover, we cannot assure that we will be able to successfully commercialize our deucrictibant product candidate, if approved for marketing. This is due to numerous risks and uncertainties associated with developing drugs. See “ITEM 3. KEY INFORMATION: — D. Risk factors.” in our Annual Report and under “Risk factors” in any other periodic filings with the Securities and Exchange Commission for a discussion of these risks and uncertainties.
General and administrative expenses
We anticipate that we will continue to incur significant general and administrative expenses as we advance our research and development portfolio towards potential commercialization. General and administrative expenses consist of the following:
We expect our total general and administrative expenses to increase in 2026, primarily due to the build out of our commercial organization.
Share-based compensation expenses
In 2016, we implemented an Equity Incentive Plan (the Plan), in order to advance the interests of our shareholders by enhancing our ability to attract, retain and motivate persons who are expected to make important contributions to us and by providing such persons with performance-based incentives that are intended to better align the interests of such persons with those of our shareholders. In order to incentivize our directors and employees, our Board adopted the Pharvaris N.V. 2021 Equity Incentive Plan (the 2021 Plan) for employees, consultants and directors prior to the completion of our initial public offering (IPO). The 2021 Plan became effective upon our conversion from Pharvaris B.V. into Pharvaris N.V., which occurred prior to the consummation of our IPO. The 2021 Plan provides for the grant of options, stock appreciation rights, restricted stock, RSUs, performance stock awards, other stock-based awards, performance cash awards, and substitute awards. The fair values of these instruments are recognized as personnel expenses in either research and development expenses or general and administrative expenses.
3
Result of operations
The financial information shown below was derived from our unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2026 and 2025 included as Exhibit 99.3 to this Report on Form 6-K. The discussion below should be read along with these unaudited condensed consolidated interim financial statements, and it is qualified in its entirety by reference to them.
Comparison of the three months ended June 30, 2026 and June 30, 2025.
|
|
For the three months ended |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
% |
|
||||
|
|
€ |
|
|
€ |
|
|
€ |
|
|
|
|
||||
Research and development expenses |
|
|
(35,000,168 |
) |
|
|
(29,607,908 |
) |
|
|
(5,392,260 |
) |
|
|
18 |
% |
General and administrative expenses |
|
|
(15,788,119 |
) |
|
|
(10,765,189 |
) |
|
|
(5,022,930 |
) |
|
|
47 |
% |
Total operating expenses |
|
|
(50,788,287 |
) |
|
|
(40,373,097 |
) |
|
|
(10,415,190 |
) |
|
|
26 |
% |
Operating loss |
|
|
(50,788,287 |
) |
|
|
(40,373,097 |
) |
|
|
(10,415,190 |
) |
|
|
26 |
% |
Finance income / (expense) |
|
|
3,547,758 |
|
|
|
(4,904,807 |
) |
|
|
8,452,565 |
|
|
|
(172 |
)% |
Loss before tax |
|
|
(47,240,529 |
) |
|
|
(45,277,904 |
) |
|
|
(1,962,625 |
) |
|
|
4 |
% |
Income taxes |
|
|
(602,200 |
) |
|
|
(202,782 |
) |
|
|
(399,418 |
) |
|
|
197 |
% |
Loss for the period |
|
|
(47,842,729 |
) |
|
|
(45,480,686 |
) |
|
|
(2,362,043 |
) |
|
|
5 |
% |
Revenues
We did not generate any revenues for the three months ended June 30, 2026 and June 30, 2025.
Research and development expenses
|
|
For the three months ended |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
% |
|
||||
|
|
€ |
|
|
€ |
|
|
€ |
|
|
|
|
||||
Personnel |
|
|
(10,761,205 |
) |
|
|
(9,351,648 |
) |
|
|
(1,409,557 |
) |
|
|
15 |
% |
Clinical |
|
|
(20,769,302 |
) |
|
|
(14,712,960 |
) |
|
|
(6,056,342 |
) |
|
|
41 |
% |
Nonclinical |
|
|
(1,053,570 |
) |
|
|
(2,858,075 |
) |
|
|
1,804,505 |
|
|
|
(63 |
)% |
Manufacturing |
|
|
(1,342,173 |
) |
|
|
(2,571,095 |
) |
|
|
1,228,922 |
|
|
|
(48 |
)% |
License fees |
|
|
(1,000,000 |
) |
|
|
— |
|
|
|
(1,000,000 |
) |
|
|
100 |
% |
Intellectual Property |
|
|
(73,918 |
) |
|
|
(114,130 |
) |
|
|
40,212 |
|
|
|
(35 |
)% |
Total research and development |
|
|
(35,000,168 |
) |
|
|
(29,607,908 |
) |
|
|
(5,392,260 |
) |
|
|
18 |
% |
Research and development expenses increased from €29.6 million for the three months ended June 30, 2025 to €35.0 million for the three months ended June 30, 2026. The increase primarily relates to increased clinical, personnel expenses, and licensing fees, offset by decreases in nonclinical and manufacturing expenses.
For the three months ended June 30, 2026 and 2025, personnel expenses were €10.8 million and €9.4 million, respectively, an increase of €1.4 million. The increase in personnel expenses is primarily driven by the hiring of additional employees to support the progression of the regulatory filings and medical affairs activities in preparation for the potential launch of the IR product. Personnel expenses include €2.9 million of share-based compensation versus €2.8 million in the prior-year period.
For the three months ended June 30, 2026 and 2025, clinical expenses were €20.8 million and €14.7 million, respectively. This represents an increase of €6.1 million, primarily due to higher spending on the conduct of the IR extension, the XR long-term, open-label, and the CREAATE (AAE) clinical studies, plus additional activities to support the progression of the regulatory filing and potential launch of the IR product offset by completion of the RAPIDe-3 (IR) Phase 3 clinical trial.
4
For the three months ended June 30, 2026 and 2025, manufacturing expenses were €1.3 million and €2.6 million, respectively. This represents a decrease of €1.2 million, primarily due to a decrease in XR manufacturing activities.
For the three months ended June 30, 2026 and 2025, nonclinical expenses were €1.1 million and €2.9 million, respectively. This represents a decrease of €1.8 million, primarily due to decreased work performed on discovery programs.
The following table summarizes our research and development expenses by project for the three months ended June 30, 2026 and 2025:
|
|
Three months ended June 30, |
|
||||||||||
|
|
2026 |
|
2025 |
|
Change |
|
% |
|
||||
Project-Specific Expenses |
|
€ |
|
€ |
|
€ |
|
|
|
||||
On-Demand (IR) |
|
|
(6,760,034 |
) |
|
(4,688,991 |
) |
|
(2,071,043 |
) |
|
44 |
% |
Prophylaxis (XR) |
|
|
(8,511,379 |
) |
|
(7,864,089 |
) |
|
(647,290 |
) |
|
8 |
% |
AAE |
|
|
(2,201,220 |
) |
|
(384,630 |
) |
|
(1,816,590 |
) |
|
472 |
% |
Unallocated Expenses |
|
|
|
|
|
|
|
|
|
||||
Personnel |
|
|
(10,761,205 |
) |
|
(9,351,648 |
) |
|
(1,409,557 |
) |
|
15 |
% |
Other |
|
|
(6,766,330 |
) |
|
(7,318,550 |
) |
|
552,220 |
|
|
(8 |
)% |
Total research and development expenses |
|
|
(35,000,168 |
) |
|
(29,607,908 |
) |
|
(5,392,260 |
) |
|
18 |
% |
The On-Demand (IR) project-specific expenses increase of €2.1 million versus the prior year period is primarily due to higher spending on the conduct of the IR extension clinical study, a licensing fee and activities to support the progression of the regulatory filing and potential launch of the IR product offset by completion of the RAPIDe-3 (IR) Phase 3 clinical trial.
The Prophylaxis (XR) project-specific expenses increase of €0.6 million versus the prior year period is primarily due to by an increase in the XR long-term, open-label clinical study offset by the completion and wind down of Phase 1 through Phase 3 XR clinical trials and a decrease in manufacturing expenses.
The AAE project-specific expenses increase of €1.8 million versus the prior year period is primarily due to the commencement and progress of the CREAATE trial, a global, pivotal Phase 3 study.
General and administrative expenses
|
|
For the three months ended June 30, |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
% |
|
||||
|
|
€ |
|
|
€ |
|
|
€ |
|
|
|
|
||||
Personnel |
|
|
(7,503,343 |
) |
|
|
(5,775,619 |
) |
|
|
(1,727,724 |
) |
|
|
30 |
% |
Professional |
|
|
(3,281,897 |
) |
|
|
(1,686,774 |
) |
|
|
(1,595,123 |
) |
|
|
95 |
% |
Insurance, facilities and office |
|
|
(1,705,557 |
) |
|
|
(1,389,322 |
) |
|
|
(316,235 |
) |
|
|
23 |
% |
Accounting, tax and auditing fees |
|
|
(541,938 |
) |
|
|
(743,906 |
) |
|
|
201,968 |
|
|
|
(27 |
)% |
Travel |
|
|
(469,521 |
) |
|
|
(274,070 |
) |
|
|
(195,451 |
) |
|
|
71 |
% |
Consulting fees |
|
|
— |
|
|
|
(28,497 |
) |
|
|
28,497 |
|
|
|
(100 |
)% |
Other |
|
|
(2,285,863 |
) |
|
|
(867,001 |
) |
|
|
(1,418,862 |
) |
|
|
164 |
% |
Total general and administrative |
|
|
(15,788,119 |
) |
|
|
(10,765,189 |
) |
|
|
(5,022,930 |
) |
|
|
47 |
% |
General and administrative expenses increased from €10.8 million for the three months ended June 30, 2025 to €15.8 million for the three months ended June 30, 2026. The increase in general and administrative expenses is primarily due to increases in commercial personnel, and commercial and IT professional and other expenses, in support of the progression of IR towards potential launch.
For the three months ended June 30, 2026 and 2025, personnel expenses were €7.5 million and €5.8 million, respectively. The €1.7 million increase in personnel expenses is prmarily driven by share-based compensation and the hiring of commercial employees to support the potential launch of the IR product. Personnel expenses include an amount of €3.7 million of share-based compensation versus €2.7 million in the prior-year period.
5
For the three months ended June 30, 2026 and 2025, professional fees were €3.3 million and €1.7 million, respectively. This represents an increase of €1.6 million, primarily due to commercial and IT expenses supporting the progression of the IR program towards potential commercialization.
For the three months ended June 30, 2026 and 2025, other expenses were €2.3 million and €0.9 million, respectively, an increase of €1.4 million. The increase is primarily due to commercial conference and market data expenses supporting the progression of the IR program towards potential commercialization as well as advisory board expenses.
Finance income / (expense) - net
Finance income (expense) for the three months ended June 30, 2026 and 2025 was €3.5 million and (€4.9) million, respectively. The €8.5 million year-over-year variance was primarily attributable to foreign exchange losses recognized in the second quarter of 2025, driven by a devaluation of the USD versus the Euro, compared to foreign exchange gains recognized in the same period of 2026 resulting from an appreciation in value of the USD versus the Euro.
Income taxes
Income taxes are accounted for in accordance with IAS 34. The interim period is considered part of a larger financial year, where the income tax is recognized in each interim period based on the best estimate of the weighted average annual income tax rate expected for the full financial year. The estimated tax expenses are determined based on a full-year basis and subsequently allocated using the expected full-year effective tax rate. The one-off items are recognized in full in the interim period in which they emerge. In the total interim tax charge, no distinction is made between current and deferred tax expenses/income.
The tax expense over the three months ended June 30, 2026 relates to the Company's U.S. and Dutch fiscal unity.
Comparison of the six months ended June 30, 2026 and June 30, 2025
|
|
For the six months ended |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
% |
|
||||
|
|
€ |
|
|
€ |
|
|
€ |
|
|
|
|
||||
Research and development expenses |
|
|
(65,161,330 |
) |
|
|
(60,522,301 |
) |
|
|
(4,639,029 |
) |
|
|
8 |
% |
General and administrative expenses |
|
|
(29,898,958 |
) |
|
|
(22,037,107 |
) |
|
|
(7,861,851 |
) |
|
|
36 |
% |
Total operating expenses |
|
|
(95,060,288 |
) |
|
|
(82,559,408 |
) |
|
|
(12,500,880 |
) |
|
|
15 |
% |
Operating loss |
|
|
(95,060,288 |
) |
|
|
(82,559,408 |
) |
|
|
(12,500,880 |
) |
|
|
15 |
% |
Finance (expense)/income |
|
|
8,892,193 |
|
|
|
(8,756,652 |
) |
|
|
17,648,845 |
|
|
|
(202 |
)% |
Loss before tax |
|
|
(86,168,095 |
) |
|
|
(91,316,060 |
) |
|
|
5,147,965 |
|
|
|
(6 |
)% |
Income taxes |
|
|
(875,307 |
) |
|
|
(505,449 |
) |
|
|
(369,858 |
) |
|
|
73 |
% |
Loss for the period |
|
|
(87,043,402 |
) |
|
|
(91,821,509 |
) |
|
|
4,778,107 |
|
|
|
(5 |
)% |
Revenues
We did not generate any revenues for the six months ended June 30, 2026 and June 30, 2025.
6
Research and development expenses
|
|
For the six months ended |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
% |
|
||||
|
|
€ |
|
|
€ |
|
|
€ |
|
|
|
|
||||
Personnel |
|
|
(20,750,961 |
) |
|
|
(17,777,098 |
) |
|
|
(2,973,863 |
) |
|
|
17 |
% |
Clinical |
|
|
(35,401,888 |
) |
|
|
(32,049,342 |
) |
|
|
(3,352,546 |
) |
|
|
10 |
% |
Manufacturing |
|
|
(5,445,858 |
) |
|
|
(5,799,627 |
) |
|
|
353,769 |
|
|
|
(6 |
)% |
Nonclinical |
|
|
(2,221,861 |
) |
|
|
(4,708,265 |
) |
|
|
2,486,404 |
|
|
|
(53 |
)% |
License fees |
|
|
(1,000,000 |
) |
|
|
— |
|
|
|
(1,000,000 |
) |
|
|
100 |
% |
Intellectual Property |
|
|
(340,762 |
) |
|
|
(187,969 |
) |
|
|
(152,793 |
) |
|
|
81 |
% |
Total research and development |
|
|
(65,161,330 |
) |
|
|
(60,522,301 |
) |
|
|
(4,639,029 |
) |
|
|
8 |
% |
Research and development expenses increased from €60.5 million for the six months ended June 30, 2025, to €65.2 million for the six months ended June 30, 2026. The increase primarily relates to increased personnel and clinical expenses and licensing fees, offset by a decrease in nonclinical expenses.
For the six months ended June 30, 2026 and 2025, personnel expenses were €20.8 million and €17.8 million, respectively, an increase of €3.0 million. The increase in personnel expenses is primarily driven by the hiring of employees to support the progression of the regulatory filings and medical affairs activities in preparation for the potential launch of the IR product. Personnel expenses include €5.1 million of share-based compensation versus €5.0 million in the prior-year period.
For the six months ended June 30, 2026 and 2025, clinical expenses were €35.4 million and €32.0 million, respectively. This represents an increase of €3.4 million primarily due to higher spending on the conduct of the CREAATE (AAE), the XR long-term, open-label, and the IR extension clinical studies plus additional activities to support the progression of the regulatory filing and potential launch of the IR product offset by completion of the RAPIDe-3 (IR) Phase 3 clinical trial.
For the six months ended June 30, 2026 and 2025, nonclinical expenses were €2.2 million and €4.7 million, respectively. This represents a decrease of €2.5 million which primarily relates to a decline in nonclinical discovery research.
The following table summarizes our research and development expenses by project for the six months ended June 30, 2026 and 2025:
|
|
Six months ended June 30, |
|
||||||||||
|
|
2026 |
|
2025 |
|
Change |
|
% |
|
||||
Project-Specific Expenses |
|
€ |
|
€ |
|
€ |
|
|
|
||||
On-Demand (IR) |
|
|
(11,271,967 |
) |
|
(13,869,345 |
) |
|
2,597,378 |
|
|
(19 |
)% |
Prophylaxis (XR) |
|
|
(16,877,971 |
) |
|
(15,924,778 |
) |
|
(953,193 |
) |
|
6 |
% |
AAE |
|
|
(4,544,725 |
) |
|
(633,018 |
) |
|
(3,911,707 |
) |
|
618 |
% |
Unallocated Expenses |
|
|
|
|
|
|
|
|
|
||||
Personnel |
|
|
(20,750,961 |
) |
|
(17,777,098 |
) |
|
(2,973,863 |
) |
|
17 |
% |
Other |
|
|
(11,715,706 |
) |
|
(12,318,062 |
) |
|
602,356 |
|
|
(5 |
)% |
Total research and development expenses |
|
|
(65,161,330 |
) |
|
(60,522,301 |
) |
|
(4,639,029 |
) |
|
8 |
% |
The On-Demand (IR) project-specific expenses decrease of €2.6 million versus the prior year period is primarily due to completion of the RAPIDe-3 (IR) Phase 3 clinical trial offset by higher spending on the conduct of the IR extension clinical study, a licensing fee, and activities to support the progression of the regulatory filing and potential launch of the IR product.
The Prophylaxis (XR) project-specific expenses increase of €1.0 million versus the prior year period is primarily due to by an increase in the XR long-term, open-label clinical study offset by the completion and wind down of Phase 1 through Phase 3 XR clinical trials and decreases in manufacturing and nonclinical development activities.
The AAE project-specific expenses increase of €3.9 million versus the prior year period is primarily due to the commencement and progress of the CREAATE trial.
7
General and administrative expenses
|
|
For the six months ended |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
% |
|
||||
|
|
€ |
|
|
€ |
|
|
€ |
|
|
|
|
||||
Personnel |
|
|
(13,750,840 |
) |
|
|
(10,804,858 |
) |
|
|
(2,945,982 |
) |
|
|
27 |
% |
Professional fees |
|
|
(6,855,363 |
) |
|
|
(4,290,920 |
) |
|
|
(2,564,443 |
) |
|
|
60 |
% |
Insurance, facilities and office |
|
|
(3,025,469 |
) |
|
|
(2,740,083 |
) |
|
|
(285,386 |
) |
|
|
10 |
% |
Accounting, tax and auditing fees |
|
|
(1,121,973 |
) |
|
|
(1,361,229 |
) |
|
|
239,256 |
|
|
|
(18 |
)% |
Travel |
|
|
(726,558 |
) |
|
|
(599,201 |
) |
|
|
(127,357 |
) |
|
|
21 |
% |
Consulting fees |
|
|
— |
|
|
|
(76,065 |
) |
|
|
76,065 |
|
|
|
(100 |
)% |
Other |
|
|
(4,418,755 |
) |
|
|
(2,164,751 |
) |
|
|
(2,254,004 |
) |
|
|
104 |
% |
Total general and administrative |
|
|
(29,898,958 |
) |
|
|
(22,037,107 |
) |
|
|
(7,861,851 |
) |
|
|
36 |
% |
General and administrative expenses increased from €22.0 million six months ended June 30, 2025, to €29.9 million for the six months ended June 30, 2026. The increase in general and administrative expenses is primarily due to increases in commercial personnel and commercial and IT professional and other expenses, in support of the progression of IR towards potential launch.
For the six months ended June 30, 2026 and 2025, personnel expenses were €13.8 million and €10.8 million, respectively. The €2.9 million increase in personnel expenses is primarily driven by share-based compensation and the hiring of commercial employees to support the potential launch of the IR product. Personnel expenses include €6.4 million of share-based compensation versus €4.7 million in the prior-year period.
For the six months ended June 30, 2026 and 2025, professional fees were €6.9 million and €4.3 million, respectively. This represents an increase of €2.6 million, primarily due to commercial and IT expenses supporting the progression of the IR program towards potential commercialization.
For the six months ended June 30, 2026 and 2025, other expenses were €4.4 million and €2.2 million, respectively, an increase of €2.3 million. The increase is primarily due to conference and market data expenses supporting the progression of the IR program towards planned commercialization as well as advisory board expenses.
Finance (expense) / income - net
Finance (expense) / income - net, for the six months ended June 30, 2026 and 2025 was €8.9 million and (€8.8) million, respectively. Of the change of €17.6 million, primarily concerns foreign exchange gains in 2026 versus a loss in 2025, given the devaluation of the USD in comparison to the EUR in prior year. Interest income represents € 1.5 million this change, impacted by higher fund availability in 2026.
Income taxes
Income taxes are accounted for in accordance with IAS 34. The interim period is considered part of a larger financial year, where the income tax is recognized in each interim period based on the best estimate of the weighted average annual income tax rate expected for the full financial year. The estimated tax expenses are determined based on a full-year basis and subsequently allocated using the expected full-year effective tax rate. The one-off items are recognized in full in the interim period in which they emerge. In the total interim tax charge, no distinction is made between current and deferred tax expenses/income.
Liquidity and Capital Resources
Since inception, we have incurred significant operating losses. For the six months ended June 30, 2026 and 2025, we incurred losses of €87.0 million and €91.8 million, respectively. Since inception, we have not generated any revenues or net cash flows from sales. We will not receive any revenues or net cash flows from sales until we successfully develop a product candidate, obtain regulatory approval and successfully commercialize it. There is no assurance that we will be able to do so.
8
To date, we have relied on the issuance of equity securities to finance our operations and internal growth. We have previously offered and sold ordinary shares and pre-funded warrants pursuant to underwritten offerings, private placements and at-the-market sales programs. In July 2025, we conducted an underwritten offering of ordinary shares and pre-funded warrants to purchase ordinary shares that generated net proceeds of approximately €160.9 million ($189 million). In May 2026, we conducted an underwritten offering of ordinary shares that generated net proceeds of approximately $124.3 million.
As of June 30, 2026 we held cash and cash equivalents of €318.3 million. Of the cash on hand, €0.1 million relates to guarantees. We do not expect positive operating cash flows in the foreseeable future and remain dependent on additional financing to fund our research and development expenses, general and administrative expenses and financing costs. We believe that the available cash balances are sufficient to execute our operating plan and strategies and to meet the anticipated working capital requirements and settle all expected liabilities for at least twelve months from the issuance date of the consolidated statements of loss and comprehensive loss. Accordingly, the consolidated statements of loss and comprehensive loss have been prepared on a going concern basis.
Our future viability is dependent on our ability to raise additional capital to finance operations. We will need to finance our operations through public or private securities offerings, debt financings or other sources, which may include licensing, collaborations or other strategic transactions or arrangements. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on terms acceptable to us, if at all. If we are unable to obtain funding, we could be forced to delay, reduce, or eliminate some or all of our research and development programs for product candidates, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations.
Our contractual obligations and commitments as of June 30, 2026 amounted to €118 million primarily related to research and development contracts.
Cash Flows
Comparison for the six months ended June 30, 2026 and 2025.
The following table sets forth our primary sources and uses of our cash and cash equivalents for each of the periods set forth below:
|
For the six months ended |
|
||||||||||||
|
2026 |
|
|
2025 |
|
Change |
|
|
% |
|
||||
|
€ |
|
|
€ |
|
€ |
|
|
|
|
||||
Net cash flows used in operating activities |
|
(86,566,932 |
) |
|
|
(68,451,963 |
) |
|
(18,114,969 |
) |
|
|
26 |
% |
Net cash flows used in investing activities |
|
(79,004 |
) |
|
|
(144,367 |
) |
|
65,363 |
|
|
|
(45 |
)% |
Net cash flows provided by (used in) financing activities |
|
105,812,502 |
|
|
|
(98,347 |
) |
|
105,910,849 |
|
|
|
(107691 |
)% |
Net increase (decrease) in cash and cash equivalents |
|
19,166,566 |
|
|
|
(68,694,677 |
) |
|
87,861,243 |
|
|
|
(128 |
)% |
Cash and cash equivalents at the beginning of the period |
|
291,678,888 |
|
|
|
280,728,037 |
|
|
10,950,851 |
|
|
|
4 |
% |
Effect of exchange rate changes |
|
7,436,999 |
|
|
|
(12,461,675 |
) |
|
19,898,674 |
|
|
|
(160 |
)% |
Cash and cash equivalents at the end of the period |
|
318,282,453 |
|
|
|
199,571,685 |
|
|
118,710,768 |
|
|
|
59 |
% |
Operating activities
Net cash used in operating activities was €86.6 million for the six months ended June 30, 2026 and primarily consisted of a net loss before taxes of €86.2 million adjusted for share-based compensation of €11.5 million, net foreign exchange gain of €6.7 million and finance costs of €0.1 million, an increase in other current assets of €1.5 million and decreases in trade and other payables of €5.8 million and increase in accrued liabilities of €0.8 million as well as other changes in net working capital.
Net cash used in operating activities was €68.5 million for the six months ended June 30, 2025 and primarily consisted of a net loss before taxes of €91.3 million adjusted for share-based compensation of €9.6 million, net foreign exchange losses of €12.0 million and finance income of €0.4 million, an increase in other current assets of €0.4 million and increase in accrued liabilities of €0.9 million and other changes in net working capital.
Financing activities
9
During May, 2026, we entered into an underwriting agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC as representatives of the underwriters named therein, pursuant to which we agreed to issue and sell in an underwritten offering 4,455,863 ordinary shares, par value €0.12 per share (which includes the exercise in full by the underwriters of their option to purchase up to an additional 581,199 ordinary shares). The offering closed on May 11, 2026, and we generated net proceeds of approximately €105.7 million ($124.3 million), after deducting bank fees of approximately €6.7 million ($7.9 million).
Off-Balance Sheet Arrangements
As of June 30, 2026, we did not have any off-balance sheet arrangements other than the disclosed commitments.
Quantitative and Qualitative Disclosures About Market Risk
During the six months ended June 30, 2026, there were no significant changes to our quantitative and qualitative disclosures about market risk from those reported in “Item 11. Quantitative and Qualitative Disclosures About Market Risk” in the Annual Report.
Critical Accounting Estimates and Judgments
There have been no material changes to the significant accounting policies and estimates described in Note 2.19 to our consolidated financial statements in the Annual Report.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this management’s discussion and analysis are or may be forward-looking statements with respect to us, our industry and our business that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this management’s discussion and analysis, including statements regarding our future financial condition, results of operations and/or business achievements, including, without limitation, statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will,” “intend” and similar expressions are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Such forward-looking statements involve unknown risks, uncertainties and other factors which may cause our actual results, financial condition, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Factors that might cause such a difference include, but are not limited to:
10
You should refer to “ITEM 3. Key information—D. Risk factors.” section of our Annual Report and under “Risk factors” in any other periodic filings with the Securities and Exchange Commission for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking
11
statements. As a result of these factors, we cannot assure you that the forward-looking statements in this management’s discussion and analysis will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.
We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
In addition, statements that “we believe” and other similar statements reflect our belief and opinions on the relevant subject. These statements are based upon information available to us as of the date of this management’s discussion and analysis, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
12
Exhibit 99.3
Pharvaris N.V.
Unaudited Condensed Consolidated Interim Financial Statements
For the six months ended June 30, 2026
Contents
Unaudited condensed consolidated statement of loss and other comprehensive loss |
|
|
|
Unaudited condensed consolidated statement of financial position |
|
|
|
Unaudited condensed consolidated statement of changes in equity |
|
|
|
Unaudited condensed consolidated statement of cash flows |
|
|
|
Notes to the unaudited condensed consolidated interim financial statements |
|
|
|
2
Unaudited condensed consolidated statement of loss and other comprehensive loss
|
|
|
Three months ended June 30, |
|
Six months ended June 30, |
|
|||||||||
|
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
|||||
|
Notes |
|
€ |
|
€ |
|
€ |
|
€ |
|
|||||
Research and development expenses |
|
3 |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
General and administrative expenses |
|
4 |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Total operating expenses |
|
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
Finance income/ (expense) |
|
6 |
|
|
|
|
( |
) |
|
|
|
( |
) |
||
Loss before income tax |
|
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
Income taxes |
|
7 |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Net Loss |
|
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|||||
Items that may be reclassified to profit or loss: |
|
|
|
|
|
|
|
|
|
|
|||||
Exchange (losses) gains arising on translation of foreign operations |
|
|
|
|
|
( |
) |
|
|
|
( |
) |
|||
Total comprehensive loss attributable to: |
|
|
|
|
|
|
|
|
|
|
|||||
Equity holders of the Company |
|
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
Loss per share attributable to the equity holders of the Company during the periods |
|
|
|
|
|
|
|
|
|
|
|||||
Basic and diluted loss per share: |
19 |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
3
Unaudited condensed consolidated statement of financial position
|
|
|
|
|
June 30, |
|
|
December 31, |
|
|||
|
|
Notes |
|
|
€ |
|
|
€ |
|
|||
Assets |
|
|
|
|
|
|
|
|
|
|||
Non-current assets |
|
|
|
|
|
|
|
|
|
|||
Property, plant and equipment |
|
|
8 |
|
|
|
|
|
|
|
||
Right of use assets |
|
|
9 |
|
|
|
|
|
|
|
||
Deferred tax assets |
|
|
7 |
|
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
|
|
|
|||
Receivables |
|
|
10 |
|
|
|
|
|
|
|
||
Other current assets |
|
|
11 |
|
|
|
|
|
|
|
||
Cash and cash equivalents |
|
|
12 |
|
|
|
|
|
|
|
||
Current tax receivable |
|
|
10 |
|
|
|
|
|
|
|
||
Total assets |
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|||
Equity and liabilities |
|
|
|
|
|
|
|
|
|
|||
Equity |
|
|
|
|
|
|
|
|
|
|||
Share capital |
|
|
13 |
|
|
|
|
|
|
|
||
Share premium |
|
|
|
|
|
|
|
|
|
|||
Other reserves |
|
|
|
|
|
|
|
|
|
|||
Currency translation reserve |
|
|
|
|
|
|
|
|
( |
) |
||
Accumulated loss |
|
|
|
|
|
( |
) |
|
|
( |
) |
|
Total equity |
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|||
Long term liabilities |
|
|
|
|
|
|
|
|
|
|||
Non-current lease liability |
|
|
9 |
|
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
|
|
|
|||
Trade and other payables |
|
|
14 |
|
|
|
|
|
|
|
||
Accrued liabilities |
|
|
15 |
|
|
|
|
|
|
|
||
Current lease liability |
|
|
9 |
|
|
|
|
|
|
|
||
Current tax payable |
|
|
|
|
|
|
|
|
|
|||
Total liabilities |
|
|
|
|
|
|
|
|
|
|||
Total equity and liabilities |
|
|
|
|
|
|
|
|
|
|||
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
4
Unaudited condensed consolidated statement of changes in equity
For the three months ended June 30, 2026 and June 30, 2025
|
|
|
|
|
Share |
|
|
Share |
|
|
Other |
|
|
Currency |
|
|
Accumulated |
|
|
Total |
|
|||||||
|
|
Notes |
|
|
€ |
|
|
€ |
|
|
€ |
|
|
€ |
|
|
€ |
|
|
€ |
|
|||||||
Balance at January 1, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||||
Net Loss |
|
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
|||||
Currency translation reserve |
|
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
( |
) |
|
— |
|
|
|
( |
) |
|||||
Share-based payments |
|
|
18 |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Settlement of share-based payments |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
|||
Balance at June 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|||||
Balance at January 1, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|||||
Net Loss |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
|
Issue of share capital |
|
|
13 |
|
|
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Transaction costs on issue of shares |
|
|
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
Currency translation reserve |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|||
Settlement of share-based payments |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
|||
Share-based payments |
|
|
18 |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Balance at June 30, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||||
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
5
Unaudited condensed consolidated statement of cash flows
For the six months ended June 30, 2026 and 2025
|
|
|
|
2026 |
|
|
2025 |
|
||
|
|
Notes |
|
€ |
|
|
€ |
|
||
Operating activities |
|
|
|
|
|
|
|
|
||
Loss before tax |
|
|
|
|
( |
) |
|
|
( |
) |
Non-cash adjustments to reconcile loss before tax to net cash flows from operations: |
|
|
|
|
|
|
|
|
||
Share-based payment expense |
|
18 |
|
|
|
|
|
|
||
Depreciation expense |
|
4 |
|
|
|
|
|
|
||
Net foreign exchange (gain) loss |
|
|
|
|
( |
) |
|
|
|
|
Finance costs (income) |
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
||
Changes in working capital: |
|
|
|
|
|
|
|
|
||
Increase in receivables |
|
|
|
|
( |
) |
|
|
( |
) |
Decrease (increase) in other current assets |
|
|
|
|
|
|
|
( |
) |
|
(Decrease ) increase in trade and other payables |
|
|
|
|
( |
) |
|
|
|
|
Increase in accrued liabilities |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
||
Income taxes (paid) received |
|
|
|
|
( |
) |
|
|
|
|
(Paid) received interest |
|
|
|
|
( |
) |
|
|
|
|
Net cash flows used in operating activities |
|
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
||
Investing activities |
|
|
|
|
|
|
|
|
||
Purchase of property, plant and equipment |
|
8 |
|
|
( |
) |
|
|
( |
) |
Net cash flows used in investing activities |
|
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
||
Financing activities |
|
|
|
|
|
|
|
|
||
Proceeds from issue of shares |
|
13 |
|
|
|
|
|
|
||
Transaction costs on issue of shares |
|
|
|
|
( |
) |
|
|
|
|
Payment of principal portion of lease liabilities |
|
9 |
|
|
( |
) |
|
|
( |
) |
Net cash flows provided by (used in) financing activities |
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
||
Net increase (decrease) in cash and cash equivalents |
|
|
|
|
|
|
|
( |
) |
|
Cash and cash equivalents at the beginning of the period |
|
|
|
|
|
|
|
|
||
Effect of exchange rate changes |
|
|
|
|
|
|
|
( |
) |
|
Cash and cash equivalents at the end of the period |
|
12 |
|
|
|
|
|
|
||
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
6
Notes to the unaudited condensed consolidated interim financial statements
1. Corporate and Group information
This section provides general corporate and group information about Pharvaris N.V. and its subsidiaries.
1.1 Corporate information
Pharvaris N.V. was incorporated on
The Company’s registered office is located at Emmy Noetherweg 2, Leiden. The Company is registered at the Chamber of Commerce under file number 64239411.
Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.
The unaudited condensed consolidated interim financial statements of Pharvaris N.V. (the “Company” or “Pharvaris”) and its subsidiaries (collectively, “The Group”) as of June 30, 2026, and December 31, 2025, and for the three and six months ended June 30, 2026 and 2025 were authorized for issue in accordance with a resolution of the directors on August 12, 2026.
1.2 Group information
Subsidiaries
The unaudited condensed consolidated interim financial statements of the Group include:
|
|
|
|
Country of |
|
% of equity interest as |
||
Name |
|
Legal seat |
|
incorporation |
|
2026 |
|
2025 |
|
|
|
|
|||||
|
|
|
|
|||||
|
|
|
|
|||||
|
|
|
|
|||||
|
|
|
|
|||||
*Pharvaris Pharmaceuticals, Inc was incorporated in June 2025
The ultimate parent company of the Group is Pharvaris N.V., which is based in the Netherlands.
2. Summary of significant accounting policies
2.1 Basis of preparation
The unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (IASB) and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2025 (“last annual financial statements”). These unaudited condensed consolidated interim financial statements do not include all the information required for a complete set of financial statements prepared in accordance with IFRS as issued by the IASB.
However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual financial statements.
The unaudited condensed consolidated interim financial statements have been prepared on a historical cost basis. Unless otherwise stated, the unaudited condensed consolidated interim financial statements are presented in euros and all values are rounded to the nearest EUR (€), except per share amounts.
2.2 Going concern
Management assessed the Company’s ability to fund its operations for a period of at least 12 months after the date of signing these financial statements. Management has not identified significant going concern risks. The financial statements of the Company have been prepared on the basis of the going concern assumption based on its existing funding, taking into account the Company’s current cash position and the projected cash flows based on the activities under execution on the basis of Pharvaris’ business plan and budget.
7
2.3 Use of judgements and estimates
In preparing these unaudited condensed consolidated interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.
The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.
2.4 Change in material accounting policies
The accounting policies applied in these unaudited condensed consolidated interim financial statements are the same as those applied in the consolidated financial statements for the year ended December 31, 2025.
Amendment to IFRS 9 and IFRS 7 - Classification and Measurement of Financial Instruments
These amendments clarify the requirements for the timing of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic cash transfer system; clarify and add further guidance for assessing whether a financial asset meets the solely payments of principal and interest (SPPI) criterion; add new disclosures for certain instruments with contractual terms that can change cash flows (such as some instruments with features linked to the achievement of environment, social and governance (ESG) targets); and make updates to the disclosures for equity instruments designated at Fair Value through Other Comprehensive Income (FVOCI).
The amendment is effective for reporting periods beginning on or after January 1, 2026. The amendments did not have a material impact on the Group.
New standards and interpretations issued not yet effective
IFRS 18, Presentation and Disclosure in Financial Statements
This is the new standard on presentation and disclosure in financial statements, with a focus on updates to the statement of profit or loss. The key new concepts introduced in IFRS 18 relate to the structure of the statement of profit or loss; required disclosures in the financial statements for certain profit or loss performance measures that are reported outside an entity’s financial statements (that is, management-defined performance measures); and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general.
The amendment is effective for reporting periods beginning on or after January 1, 2027. The amendments are being assessed by the Group.
There are no other IFRS or IFRIC interpretations that are not yet effective and that are expected to have a material impact to the interim consolidated financial statements.
3. Research and development expenses
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
|
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
||||
|
|
€ |
|
€ |
|
€ |
|
€ |
|
||||
Clinical |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Personnel (Note 5) |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Nonclinical |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Manufacturing |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
License fees |
|
|
( |
) |
|
|
|
( |
) |
|
|
||
Intellectual Property |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Development expenses are currently not capitalized but are recorded in the condensed consolidated statements of profit or loss and other comprehensive loss because the recognition criteria for capitalization are not met.
Clinical expenses include costs of conducting and managing our sponsored clinical trials, including clinical investigator cost, costs of clinical sites, and costs for CRO’s assisting with our clinical development programs and travel expenses.
Manufacturing expenses include costs related to manufacturing of active pharmaceutical ingredients and manufacturing of the products used in our clinical trials and research and development activities as well as travel expenses.
Nonclinical expenses include costs of our outsourced discovery and nonclinical development studies and associated
8
travel expenses.
Licensing costs consist of milestone payments reflecting the submission of the New Drug Application with the FDA in the first half of 2026.
4. General and administrative expenses
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
|
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
||||
|
|
€ |
|
€ |
|
€ |
|
€ |
|
||||
Personnel (Note 5) |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Professional fees |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Insurance, facilities and office |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Accounting, tax and auditing fees |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Travel |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Consulting |
|
|
|
|
( |
) |
|
|
|
( |
) |
||
Other |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Since 2022, the Group entered into a number of short-term rental arrangements, the expenses are included in "Other expenses".
Depreciation expense for the six months ended June 30, 2026 and 2025 was €
5. Personnel expenses
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
|
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
||||
|
|
€ |
|
€ |
|
€ |
|
€ |
|
||||
Wages and salaries |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Share-based payments |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Other social security charges |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Pension charges |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Other employee related costs |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
The average number of staff (in FTEs) employed by the Group in the three months ended June 30, 2026 was
6. Finance income/ (expense)
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
|
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
||||
|
|
€ |
|
€ |
|
€ |
|
€ |
|
||||
Foreign exchange differences |
|
|
|
|
( |
) |
|
|
|
( |
) |
||
Interest and other income over bank balances |
|
|
|
|
|
|
|
|
|
||||
Other finance expenses |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
|
|
|
|
|
( |
) |
|
|
|
( |
) |
||
7. Income taxes
Income taxes are accounted for in line with IAS 34. The interim period is considered part of a larger financial year, where the income tax is recognized in each interim period based on the best estimate of the weighted average annual income tax rate expected for the full financial year. The estimated tax expenses are determined based on a full-year basis (P&L) and subsequently allocated using the expected full year effective tax rate. The discrete items are
9
recognized in full in the interim period in which they emerge. In the total interim tax charge, no distinction is made between current and deferred tax expenses/ income.
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
For the three months ended June 30, |
|
|
For the six months ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
€ |
|
|
€ |
|
|
€ |
|
|
€ |
|
||||
Income tax expense |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Deferred tax charge |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Income tax expense |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
The tax expense over the three and six months ended June 30, 2026 and 2025 relates to the Company's U.S. and Dutch subsidiaries as the result of a cost-plus agreement between the Company's principal entity and the U.S. and the Dutch subsidiaries, resulting in an estimated taxable profit in the U.S. and the Netherlands.
Reconciliation of income tax benefit at statutory tax rate and the income tax expense as reported in the unaudited condensed consolidated statement of profit or loss and other comprehensive income is as follows:
|
|
For the three months ended June 30, |
|
For the six months ended |
|
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
||||
|
|
€ |
|
€ |
|
€ |
|
€ |
|
||||
Loss before income tax |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Income tax at statutory income tax rate in the Netherlands ( |
|
|
|
|
|
|
|
|
|
||||
Effect of tax rates in other countries |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Deferred tax assets recognition effects |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Temporary differences for which no deferred tax assets/liabilities have been recognized |
|
|
|
|
|
|
|
|
|
||||
Non-deductible expenses |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Transfer Pricing adjustment |
|
|
|
|
( |
) |
|
|
|
( |
) |
||
Prior period adjustments |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Income tax expense |
|
|
( |
) |
|
( |
) |
|
( |
) |
|
( |
) |
Income tax expense is recognized based on management’s estimate of the weighted average effective annual income tax rate expected for the full financial year, bearing in mind the impact of non-discrete and discrete items. Non discrete items in the income tax expense are recognized based on management’s estimate of the weighted average effective annual income tax rate expected for the full financial year. Discrete items in the income tax expense are recognized at the applicable statutory tax rate.
The (estimated) average annual tax rate used for the six months ended June 30, 2026 was
The current period losses for which no deferred tax asset has been recognized mainly consists of the unrecognized tax effect of losses incurred in Switzerland. The differences in the overseas tax rates are due to the lower tax rate in Switzerland compared to the statutory income tax rate in the Netherlands.
Pharvaris N.V. is the head of the fiscal unity including Pharvaris Netherlands B.V. and Pharvaris Holdings B.V.
Deferred tax
Deferred taxes have been recognized to the extent that management concludes that there is sufficient probability as per IAS 12 that there will be future taxable profits available in the foreseeable future against which the unused tax losses and deductible temporary differences can be utilized.
Deferred tax assets relating to losses carried forward have not been recognized, and deferred tax assets on deductible temporary differences in excess of deferred tax liabilities on taxable temporary differences have not been recognized in the consolidated statement of profit and loss and other comprehensive income for the Dutch fiscal unity.
10
8. Property, plant and equipment
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
||
Net book value |
|
€ |
|
|
€ |
|
||
Balance at beginning of period |
|
|
|
|
|
|
||
Additions |
|
|
|
|
|
|
||
Depreciation expenses |
|
|
( |
) |
|
|
( |
) |
Balance at end of period |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
||
Cumulative depreciation |
|
€ |
|
|
€ |
|
||
As of January 1, |
|
|
( |
) |
|
|
( |
) |
Depreciation |
|
|
( |
) |
|
|
( |
) |
Balance at end of period |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
||
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
||
Cumulative Costs |
|
€ |
|
|
€ |
|
||
Balance at beginning of period |
|
|
|
|
|
|
||
Additions |
|
|
|
|
|
|
||
Balance at end of period |
|
|
|
|
|
|
||
During the six months ended June 30, 2026, the Group acquired assets with a cost of €
9. Leases
The following table provides information about the Group’s right-of-use assets:
|
|
June 30, |
|
|
December 31, 2025 |
|
||
|
|
€ |
|
|
€ |
|
||
Balance at beginning of period |
|
|
|
|
|
|
||
Remeasurement |
|
|
|
|
|
|
||
Depreciation charges |
|
|
( |
) |
|
|
( |
) |
Impact of transaction of foreign currency |
|
|
|
|
|
( |
) |
|
Balance at end of period |
|
|
|
|
|
|
||
The following table provides information about the Group’s lease liabilities at June 30, 2026:
|
|
June 30, |
|
|
December 31, |
|
||
|
|
€ |
|
|
€ |
|
||
Office leases |
|
|
( |
) |
|
|
( |
) |
Total lease liability |
|
|
( |
) |
|
|
( |
) |
Current portion |
|
|
( |
) |
|
|
( |
) |
Non-current portion |
|
|
( |
) |
|
|
( |
) |
Office leases consist of (i) a lease that was renewed on December 1, 2025 with an expiration date of November 30, 2028 for offices in Leiden, the Netherlands. The lease has a lease term of
11
The average incremental borrowing rate applied to the lease liability related to the Leiden lease was
The average incremental borrowing rate applied to the lease liability related to the U.S. lease was
Depreciation expense was €
The total expense related to short-term and low-value leases for the six months ended June 30, 2026 and 2025, was € million and €
Cash outflows related to leases during the six months ended June 30, 2026 and 2025 were €
10. Receivables
|
|
June 30, |
|
|
December 31, |
|
||
|
|
€ |
|
|
€ |
|
||
Current tax receivable |
|
|
|
|
|
|
||
VAT receivables |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
11. Other current assets
|
|
June 30, |
|
|
December 31, |
|
||
|
|
€ |
|
|
€ |
|
||
Prepayments |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
Prepayments mainly relate to prepaid insurance, prepaid research and development expenses and rent.
12. Cash and cash equivalents
As of June 30, 2026 and December 31, 2025, there were
13. Equity
On June 30, 2026, the Company’s authorized share capital amounted to €
As of June 30, 2026, the total number of issued and fully paid shares was
In April 2024, the Company entered into an at-the-market sales agreement with Leerink Partners, pursuant to which it may sell ordinary shares having an aggregate offering price of up to $
In July 2025, the Company entered into an underwriting agreement with Morgan Stanley & Co. and Leerink Partners, as representatives of the underwriters, pursuant to which the Company agreed to issue and sell (i)
12
On May 8, 2026, the Company entered into an underwriting agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC as representatives of the underwriters named therein, pursuant to which the Company agreed to issue and sell in an underwritten offering
Issued shares
|
|
June 30, |
|
|
December 31, |
|
||
|
|
Number of shares |
|
|
Number of shares |
|
||
Ordinary shares |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
14. Trade and other payables
|
|
June 30, |
|
|
December 31, |
|
||
|
|
€ |
|
|
€ |
|
||
Trade payables |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
15. Accrued liabilities
|
|
June 30, |
|
|
December 31, |
|
||
|
|
€ |
|
|
€ |
|
||
Clinical accrued liabilities |
|
|
|
|
|
|
||
Personnel related accruals |
|
|
|
|
|
|
||
Manufacturing accrued liabilities |
|
|
|
|
|
|
||
Nonclinical accrued liabilities |
|
|
|
|
|
|
||
Consulting, professional and audit liability |
|
|
|
|
|
|
||
Other accrued liabilities |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
16. Risk management activities
The Group’s risk management activities are the same as disclosed in Note 17 of the consolidated financial statements for the year ended December 31, 2025.
17. Fair values
Fair values of cash balances, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.
The fair value of the cash equivalents, Group’s financial instruments measured at fair value on recurring basis, is categorized within level 1 of the fair value hierarchy, as the valuation is based on quoted net asset values (NAV) in active markets at the reporting date.
18. Share-based payments
In 2016, the Company implemented an Equity Incentive Plan (the “Plan”) in order to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with performance-based incentives that are intended to better align the interests of such persons with those of the Company’s shareholders. This plan has been superseded by the 2021 Equity Incentive Plan (the “2021 Plan”).
13
Set out below is an overview of changes in the Stock Options and Restricted Stock Units (“RSUs”) during the six months ended June 30, 2026.
|
|
Stock Options |
|
|
RSUs |
|
||||||
|
|
Outstanding |
|
|
Weighted |
|
|
Outstanding |
|
|||
|
|
|
|
|
€ |
|
|
|
|
|||
Outstanding January 1, 2026 |
|
|
|
|
|
|
|
|
|
|||
Granted |
|
|
|
|
|
|
|
|
|
|||
Exercised (Vested and Settled) |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
Forfeited |
|
|
|
|
|
|
|
|
( |
) |
||
Outstanding June 30, 2026 |
|
|
|
|
|
|
|
|
|
|||
During the six months ended June 30, 2026, a total of
During the six months ended June 30, 2026,
During the six months ended June 30, 2026,
During the six months ended June 30, 2026,
(a) Milestone 1- the approval by the U.S. Food and Drug Administration ("FDA") of the Company's New Drug Application ("NDA") for deucrictibant immediate-release capsules for the on-demand treatment of hereditary angioedema ("HAE") attacks: Forty percent (
(b) Milestone 2 - the approval by the U.S. Food and Drug Administration ("FDA") of the Company's New Drug Application ("NDA") for deucrictibant extended-release tablets for the prophylactic treatment of hereditary angioedema ("HAE") attacks: Sixty percent (
The fair value of the RSUs is determined based on the share value per ordinary share at the grant date (or at the first trading day after the grant date if the Nasdaq Stock Exchange is not open on this date). The grant dates and share closing prices for grants during the first six months of 2026 were: January 1 (€
On March 3, 2026, a total of
On March 3, 2026, a total of
On June 1, 2026,
Milestone 1 - the approval by the U.S. Food and Drug Administration ("FDA") of the Company's New Drug Application ("NDA") for deucrictibant immediate-release capsules for the on-demand treatment of hereditary angioedema ("HAE") attacks: Forty percent (
Milestone 2 - the approval by the U.S. Food and Drug Administration ("FDA") of the Company's New Drug Application ("NDA") for deucrictibant extended-release tablets for the prophylactic treatment of hereditary angioedema ("HAE")
14
attacks: Sixty percent (
As of June 30, 2026, a total number of
For the six months ended June 30, 2026, the Group recognized €
The inputs and outputs used in the measurement of the fair value per option at each grant/ measurement date using the Black-Scholes formula (including the related number of options and the fair value of the options) were as follows:
|
|
June 1, 2026** |
|
March 3, 2026* |
|
March 3, 2026** |
|
March 12, 2025* |
|
March 12, 2025** |
|
|||||
Number of options |
|
|
|
|
|
|
|
|
|
|
|
|||||
Fair value of the options |
|
€ |
|
€ |
|
€ |
|
€ |
|
€ |
|
|||||
Fair value of the ordinary shares |
|
€ |
|
€ |
|
€ |
|
€ |
|
€ |
|
|||||
Exercise price |
|
€ |
|
€ |
|
€ |
|
€ |
|
€ |
|
|||||
Expected volatility (%) |
|
|
% |
|
% |
|
% |
|
% |
|
% |
|||||
Expected life (years) |
|
|
|
|
|
|
|
|
||||||||
Risk-free interest rate (%) |
|
|
% |
|
% |
|
% |
|
% |
|
% |
|||||
Expected dividend yield |
|
|
|
|
|
|
|
|
|
|
|
|||||
*
**
19. Basic and diluted loss per share
Basic and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of issued and outstanding ordinary shares during the three months ended June 30, 2026 and 2025.
All of the Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share attributable to ordinary stockholders as the effect of including them would be antidilutive.
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
|
|||||||||
|
|
2026 |
|
|
2025 |
|
2026 |
|
2025 |
|
||||
|
|
€ |
|
|
€ |
|
€ |
|
€ |
|
||||
Net Loss |
|
|
( |
) |
|
|
( |
) |
|
( |
) |
|
( |
) |
Weighted average number of ordinary shares outstanding |
|
|
|
|
|
|
|
|
|
|
||||
Basic and diluted loss per share |
|
|
( |
) |
|
|
( |
) |
|
( |
) |
|
( |
) |
20. Commitments and Contingencies
Claims
There are
Commitments
The Group's contractual obligations and commitments as of June 30, 2026 amounted to €
21. Related parties
Note 1.2 provides information about the Group’s structure, including details of the subsidiaries and the holding company. The following provides the total amount of transactions that have been entered into with related parties for the relevant financial period.
15
Key management personnel compensation
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
|
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
||||
|
|
€ |
|
€ |
|
€ |
|
€ |
|
||||
Short term employee benefits |
|
|
|
|
|
|
|
|
|
||||
Post employee benefits |
|
|
|
|
|
|
|
|
|
||||
Share-based payments |
|
|
|
|
|
|
|
|
|
||||
Total |
|
|
|
|
|
|
|
|
|
||||
The Company engages GrayMatters Consulting BV, a management entity for the purpose of providing key management services to the Company. This management entity is considered a related party, as it provides key management services and exercises key management functions.
The aggregate amount of expense recognized in the unaudited condensed consolidated interim financial statements related to this related party was €
The outstanding balances payable to key management personnel, or entities which they control, as per June 30, 2026 and December 31, 2025 were €
16
22. Events after the reporting period
The Company has evaluated subsequent events through August 12, 2026, which is the date the condensed consolidated interim financial statements were authorized for issuance, and did not identify any significant event after reporting period that needs to be disclosed.
17
Signatories to the unaudited condensed consolidated interim financial statements
Leiden, August 12, 2026
Pharvaris N.V.
Board of Directors
B.A.E. Modig |
R.H. Glassman |
E. Björk |
J.G.C.P. Schikan |
D.P. Meeker |
V. Monges |
|
|
18